Molecular IVD Tests See Faster Revenue Growth Than Standard IVD: Report

NEW YORK, NY — (Marketwire) — 02/01/13 — Tests aimed a molecular target for use in clinical decision-making will produce much faster revenue growth than traditional IVD tests, according to Kalorama Information. Kalorama Information said tests are a 5.2 billion dollar market and will grow 8% each year to 7.6 billion by 2017. That-s four times as fast as revenue growth in standard chemistry tests and twice as fast as immunoassay markets, according to the company-s IVD market research database.